Wedbush lowered the firm’s price target on Apellis (APLS) to $18 from $20 and keeps a Neutral rating on the shares. Overall, the Q4 report from Apellis was largely as anticipated with the company preannouncing key results in January, the firm notes. Management anticipates flat Syfovre pricing into FY26 and more limited growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $18 from $20 at Wedbush
- Apellis price target lowered to $44 from $45 at Citi
- Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
- Apellis price target raised to $48 from $45 at H.C. Wainwright
- Apellis Pharmaceuticals: Buy Rating Supported by Blockbuster Empaveli Potential, Sustainable Syfovre Growth, and Expanding Kidney Franchise